ERYTECH Pharma announces that investigators presented additional results from the pivotal Phase 2/3 clinical trial with GRASPA that add to the body of data supporting the potential benefit of GRASPA in combination with chemotherapy in the treatment of Acute Lymphoblastic Leukemia (ALL).
The post ERYTECH announces presentation of additional data at the American Society of Hematology 57th Annual Meeting appeared first on Erytech Pharma.